The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
New Therapies for Advanced Thyroid Cancer
Open accessAbstract
Thyroid cancer is the most common endocrine cancer. The discovery of new biomarkers for thyroid cancer has significantly improved the understanding of the molecular pathogenesis of thyroid cancer, thus allowing more personalized treatments for patients with thyroid cancer. Most of the recently discovered targeted therapies inhibit the known oncogenic mechanisms in thyroid cancer initiation and progression such as MAPK pathway, PI3K/Akt-mTOR pathways, or VEGF. Despite the significant advances in molecular testing and the discoveries of new and promising therapeutics, effective treatments for advanced and metastatic, iodine-refractory thyroid cancer are still lacking. Here, we aim to summarize the current understanding of the genetic alterations and the dysregulated pathways in thyroid cancer and to discuss the most recent targeted therapies and immunotherapy for advanced thyroid cancer with a promising anti-tumor activity and clinical benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013
Lim, H., Devesa, S. S., Sosa, J. A., Check, D., & Kitahara, C. M. (2017) · JAMA · doi:10.1001/jama.2017.2719 · Cited by 2,159
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C., Cabanillas, M. E., Urbanowitz, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 892
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796
Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., Alexander, E. K., Dorn, G. W., Tallini, G., Kroll, T. G., & Nikiforov, Y. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021907 · Cited by 713
Haugen, B. R. (2017) · Cancer · doi:10.1002/cncr.30360 · Cited by 683
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Soares, P., Trovisco, V., Rocha, A. S., Lima, J., Castro, P., Preto, A., Máximo, V., Botelho, T., Seruca, R., & Sobrinho-Simões, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206706 · Cited by 679
Matsui, J., Yamamoto, Y., Funahashi, Y., Tsuruoka, A., Watanabe, T., Wakabayashi, T., Uenaka, T., & Asada, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23131 · Cited by 551
Yamamoto, Y., Matsui, J., Matsushima, T., Obaishi, H., Miyazaki, K., Nakamura, K., Tohyama, O., Semba, T., Yamaguchi, A., Hoshi, S., et al. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-18 · Cited by 507 · cited 1×
“Due to its high affinity to VEGFR and FGFR, lenvatinib showed a high anti-angiogenic effects in thyroid cancer mouse model (36).”
BackgroundAnaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
Smallridge, R. C., & Copland, J. A. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.03.013 · Cited by 481
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
Liu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A. K., & Xing, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0273 · Cited by 390
Brose, M. S., Cabanillas, M. E., Cohen, E. E. W., Wirth, L. J., Riehl, T., Yue, H., Sherman, S. I., & Sherman, E. J. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30166-8 · Cited by 388
Rothenberg, S. M., McFadden, D. G., Palmer, E. L., Daniels, G. H., & Wirth, L. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2915 · Cited by 376
Donghi, R., Longoni, A., Pilotti, S., Michieli, P., Della Porta, G., & Pierotti, M. A. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116385 · Cited by 370
COOPER, D. S., SPECKER, B., HO, M., SPERLING, M., LADENSON, P. W., ROSS, D. S., AIN, K. B., BIGOS, S. T., BRIERLEY, J. D., HAUGEN, B. R., et al. (1998) · Thyroid · doi:10.1089/thy.1998.8.737 · Cited by 353
Jung, C. K., Little, M. P., Lubin, J. H., Brenner, A. V., Wells, S. A., Sigurdson, A. J., & Nikiforov, Y. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2503 · Cited by 343
Hiltzik, D., Carlson, D. L., Tuttle, R. M., Chuai, S., Ishill, N., Shaha, A., Shah, J. P., Singh, B., & Ghossein, R. A. (2006) · Cancer · doi:10.1002/cncr.21739 · Cited by 312
Okamoto, K., Kodama, K., Takase, K., Sugi, N. H., Yamamoto, Y., Iwata, M., & Tsuruoka, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.007 · Cited by 288
Biondi, B., & Cooper, D. S. (2010) · Thyroid · doi:10.1089/thy.2009.0311 · Cited by 286
β-Catenin Dysregulation in Thyroid Neoplasms
Garcia-Rostan, G., Camp, R. L., Herrero, A., Carcangiu, M. L., Rimm, D. L., & Tallini, G. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64045-x · Cited by 277
High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma
Lin, Y.-M., Sung, W.-W., Hsieh, M.-J., Tsai, S.-C., Lai, H.-W., Yang, S.-M., Shen, K.-H., Chen, M.-K., Lee, H., Yeh, K.-T., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142656 · Cited by 231
Follicular Adenoma and Carcinoma of the Thyroid Gland
McHenry, C. R., & Phitayakorn, R. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0405 · Cited by 225
Mehnert, J. M., Varga, A., Brose, M. S., Aggarwal, R. R., Lin, C.-C., Prawira, A., de Braud, F., Tamura, K., Doi, T., Piha-Paul, S. A., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5380-3 · Cited by 215
Volante, M., Landolfi, S., Chiusa, L., Palestini, N., Motta, M., Codegone, A., Torchio, B., & Papotti, M. G. (2004) · Cancer · doi:10.1002/cncr.20087 · Cited by 211
Differentiated Thyroid Cancer—Treatment: State of the Art
Schmidbauer, B., Menhart, K., Hellwig, D., & Grosse, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061292 · Cited by 205
Nikiforov, Y. E., Erickson, L. A., Nikiforova, M. N., Caudill, C. M., & Lloyd, R. V. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200112000-00002 · Cited by 199
Kim, K. B., Cabanillas, M. E., Lazar, A. J., Williams, M. D., Sanders, D. L., Ilagan, J. L., Nolop, K., Lee, R. J., & Sherman, S. I. (2013) · Thyroid · doi:10.1089/thy.2013.0057 · Cited by 197
RAS Mutations in Thyroid Cancer
Howell, G. M., Hodak, S. P., & Yip, L. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0072 · Cited by 195
Uncommon Mutation, but Common Amplifications, of the PIK3CA Gene in Thyroid Tumors
Wu, G., Mambo, E., Guo, Z., Hu, S., Huang, X., Gollin, S. M., Trink, B., Ladenson, P. W., Sidransky, D., & Xing, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2281 · Cited by 191
Cabanillas, M. E., Schlumberger, M., Jarzab, B., Martins, R. G., Pacini, F., Robinson, B., McCaffrey, J. C., Shah, M. H., Bodenner, D. L., Topliss, D., et al. (2015) · Cancer · doi:10.1002/cncr.29395 · Cited by 186
PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
Massari, F., Santoni, M., Ciccarese, C., Santini, D., Alfieri, S., Martignoni, G., Brunelli, M., Piva, F., Berardi, R., Montironi, R., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.013 · Cited by 180
Hayes, D. N., Lucas, A. S., Tanvetyanon, T., Krzyzanowska, M. K., Chung, C. H., Murphy, B. A., Gilbert, J., Mehra, R., Moore, D. T., Sheikh, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0563 · Cited by 154
Ghossein, R. A., Leboeuf, R., Patel, K. N., Rivera, M., Katabi, N., Carlson, D. L., Tallini, G., Shaha, A. R., Singh, B., & Tuttle, R. M. (2007) · Thyroid · doi:10.1089/thy.2007.0061 · Cited by 141
Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer
Hutton, J. E., Wang, X., Zimmerman, L. J., Slebos, R. J. C., Trenary, I. A., Young, J. D., Li, M., & Liebler, D. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058925 · Cited by 140
Hou, P., Ji, M., & Xing, M. (2008) · Cancer · doi:10.1002/cncr.23869 · Cited by 136
Leboeuf, R., Baumgartner, J. E., Benezra, M., Malaguarnera, R., Solit, D. B., Pratilas, C. A., Rosen, N. X., Knauf, J. A., & Fagin, J. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2825 · Cited by 130
Hanna, G. J., Busaidy, N. L., Chau, N. G., Wirth, L. J., Barletta, J. A., Calles, A., Haddad, R. I., Kraft, S., Cabanillas, M. E., Rabinowits, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2297 · Cited by 128
Immune landscape of papillary thyroid cancer and immunotherapeutic implications
Na, K. J., & Choi, H. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0532 · Cited by 127
Wendler, J., Kroiß, M., Gast, K., Kreissl, M. C., Allelein, S., Lichtenauer, U. D., Blaser, R., Spitzweg, C., Faßnacht, M., Schott, M., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0574 · Cited by 123
Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases
Bonhomme, B., Godbert, Y., Pérot, G., Ghuzlan, A. A., Bardet, S., Belleannée, G., Crinière, L., Cao, C. D., Fouilloux, G., Guyétant, S., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0254 · Cited by 113
Gunda, V., Gigliotti, B. J., Ashry, T., Ndishabandi, D., McCarthy, M., Zhou, Z., Amin, S., Lee, K. E., Stork, T., Wirth, L. J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32041 · Cited by 113
Brauner, E., Gunda, V., Borre, P. V., Zurakowski, D., Kim, Y. S., Dennett, K. V., Amin, S., Freeman, G. J., & Parangi, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7839 · Cited by 110
Ball, D. W., Jin, N. Y., Rosen, D. M., Dackiw, A. P. B., Sidransky, D., Xing, M., & Nelkin, B. D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1184 · Cited by 109
Salerno, P., Falco, V. D., Tamburrino, A., Nappi, T. C., Vecchio, G., Schweppe, R. E., Bollag, G. E., Santoro, M. M., & Salvatore, G. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0373 · Cited by 98
Schneider, T., de Wit, D., Links, T. P., van Erp, N. P., van der Hoeven, J. J. M., Gelderblom, H. A. J., Roozen, C. F. M., Bos, M., Corver, W. E., van Wezel, T., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2525 · Cited by 98
Vieira, J. M., Santos, S. C. R., Espadinha, C., Correia, I., Vág, T., Casalou, C., Cavaco, B. M., Catarino, A. L., Dias, S., & Leite, V. A. P. H. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02009 · Cited by 79
Molecular Targeted Therapies of Aggressive Thyroid Cancer
Ferrari, S. M., Fallahi, P., Politti, U., Materazzi, G., Baldini, E., Ulisse, S., Miccoli, P., & Antonelli, A. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00176 · Cited by 74
Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer
Cantara, S., Bertelli, E., Occhini, R., Regoli, M., Brilli, L., Pacini, F., Castagna, M. G., & Toti, P. (2019) · Endocrine · doi:10.1007/s12020-019-01865-5 · Cited by 65
Recombinant human thyrotropin in the management of thyroid cancer
McDougall, I. R., & Weigel, R. J. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200101000-00008 · Cited by 43
Brown, S., Hall, A., Buckley, H., Flanagan, L. M., de Castro, D. G., Farnell, K., Moss, L., Gregory, R., Newbold, K. L., Du, Y., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5541-4 · Cited by 39
mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
Hanly, E. K., Bednarczyk, R. B., Tuli, N. Y., Moscatello, A. L., Halicka, H. D., Li, J., Geliebter, J., Darżynkiewicz, Z., & Tiwari, R. K. (2015) · Oncotarget · doi:10.18632/oncotarget.4052 · Cited by 37
Karaca, Z., Tanrıverdi, F., Unluhizarci, K., Ozturk, F., Gökahmetoğlu, S., Elbüken, G., Çakır, I., Bayram, F., & Keleştimur, F. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0967 · Cited by 37
Vitale, G., Dicitore, A., Pepe, D., Gentilini, D., Grassi, E., Borghi, M. O., Gelmini, G., Cantone, M. C., Gaudenzi, G., Misso, G., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12070 · Cited by 35
Sadowski, S. M., Boufraqech, M., Zhang, L., Mehta, A. R., Kapur, P., Zhang, Y., Li, Z., Shen, M., & Kebebew, E. (2015) · Oncotarget · doi:10.18632/oncotarget.3833 · Cited by 25
Self-citationNovel treatment options for anaplastic thyroid cancer
Fallahi, P., Ruffilli, I., Elia, G., Ragusa, F., Ulisse, S., Baldini, E., Miccoli, M., Materazzi, G., Antonelli, A., & Ferrari, S. M. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1340155 · Cited by 15
Metadata
- Authors
- Laha, D., Nilubol, N., & Boufraqech, M.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2020-05-22
- Volume
- 11
- Pages
- 82-82
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W3026431630
- Cited by
- 261
- References
- 63
- FWCI
- 18.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.